Trial Profile
RANDOMIZED, OPEN, MULTICENTER, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN vs. TRABECTEDIN PLUS DOXORUBICIN IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Doxorubicin
- Indications Fibrosarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Neurofibrosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 02 Jun 2017 Results (n=198) assessing role of FAS for trabectadin in second lines of advanced soft tissue sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 16 May 2016 Primary endpoint has not been met. (Progression free survival), as per an article published in the Journal of Clinical Oncology.